WO2011006161A3 - Compositions et procédés permettant de diagnostiquer et de traiter la dégénérescence maculaire - Google Patents

Compositions et procédés permettant de diagnostiquer et de traiter la dégénérescence maculaire Download PDF

Info

Publication number
WO2011006161A3
WO2011006161A3 PCT/US2010/041720 US2010041720W WO2011006161A3 WO 2011006161 A3 WO2011006161 A3 WO 2011006161A3 US 2010041720 W US2010041720 W US 2010041720W WO 2011006161 A3 WO2011006161 A3 WO 2011006161A3
Authority
WO
WIPO (PCT)
Prior art keywords
macular degeneration
compositions
methods
diagnosing
treating macular
Prior art date
Application number
PCT/US2010/041720
Other languages
English (en)
Other versions
WO2011006161A2 (fr
Inventor
Anand Swaroop
Gonçalo ABECASIS
Wei Chen
Albert O. Edwards
Dwight Stambolian
Original Assignee
The Regents Of The University Of Michigan
Mayo Foundation For Medical Education And Research
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan, Mayo Foundation For Medical Education And Research, The Trustees Of The University Of Pennsylvania filed Critical The Regents Of The University Of Michigan
Priority to EP20100797971 priority Critical patent/EP2451983B1/fr
Priority to CA2781595A priority patent/CA2781595C/fr
Publication of WO2011006161A2 publication Critical patent/WO2011006161A2/fr
Publication of WO2011006161A3 publication Critical patent/WO2011006161A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne en général des biomarqueurs de la dégénérescence maculaire. En particulier, elle concerne une pluralité de biomarqueurs permettant de surveiller et de diagnostiquer la dégénérescence maculaire. Les compositions et les méthodes de la présente invention trouvent une utilisation dans des applications diagnostiques, thérapeutiques, de recherche et de criblage de médicaments.
PCT/US2010/041720 2009-07-10 2010-07-12 Compositions et procédés permettant de diagnostiquer et de traiter la dégénérescence maculaire WO2011006161A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20100797971 EP2451983B1 (fr) 2009-07-10 2010-07-12 Procédés permettant de diagnostiquer la dégénérescence maculaire
CA2781595A CA2781595C (fr) 2009-07-10 2010-07-12 Compositions et procedes permettant de diagnostiquer et de traiter la degenerescence maculaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22475309P 2009-07-10 2009-07-10
US61/224,753 2009-07-10

Publications (2)

Publication Number Publication Date
WO2011006161A2 WO2011006161A2 (fr) 2011-01-13
WO2011006161A3 true WO2011006161A3 (fr) 2011-06-16

Family

ID=43429871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/041720 WO2011006161A2 (fr) 2009-07-10 2010-07-12 Compositions et procédés permettant de diagnostiquer et de traiter la dégénérescence maculaire

Country Status (4)

Country Link
US (2) US8119348B2 (fr)
EP (2) EP2963128A1 (fr)
CA (1) CA2781595C (fr)
WO (1) WO2011006161A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046189A1 (en) * 2009-03-27 2012-02-23 The General Hospital Corporation Markers related to age-related macular degeneration and uses therefor
CN104293953A (zh) * 2012-05-14 2015-01-21 电子科技大学附属医院·四川省人民医院 一种老年黄斑变性疾病的筛查试剂盒
CN104293886A (zh) * 2013-07-16 2015-01-21 浙江爱易生物医学科技有限公司 一种用荧光sybr方法检测黄斑变性基因位点的试剂盒
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
BR112016025312A2 (pt) 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242794A (en) 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7312050B2 (en) 1998-10-29 2007-12-25 University Of Iowa Research Foundation Nucleic acids encoding interphotoreceptor matrix proteins
US6417342B1 (en) 1999-02-12 2002-07-09 University Of Iowa Research Foundation Macular degeneration diagnostics and therapeutics
US6593104B1 (en) 1999-02-12 2003-07-15 University Of Iowa Research Foundation Macular degeneration diagnostics and therapeutics
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
ES2316446T3 (es) 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
US7351534B2 (en) 2003-01-27 2008-04-01 Oregon Health & Sciences University Gene mutation associated with age-related macular degeneration
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
US20080318264A1 (en) 2005-09-09 2008-12-25 University Of Iowa Research Foundation Biomarkers Associated With Age-Related Macular Degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
CA2638916A1 (fr) * 2006-02-13 2007-08-23 University Of Iowa Research Foundation Variants de genes de regulation du complement permettant de predire la degenerescence maculaire liee a l'age
WO2008110828A1 (fr) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Procédé de prévention de la dégénérescence maculaire liée à l'âge (amd)
US20090111708A1 (en) * 2007-05-11 2009-04-30 Seddon Johanna M Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRANTLEY, M. A. JR. ET AL.: "Clinical phenotypes associated with the compleme nt factor H Y402H variant in age-related macular degeneration", AMERICAN JOURNAL OF OPHTHALMOLOGY., vol. 144, no. 3, 12 July 2007 (2007-07-12), pages 404 - 408, XP022219335 *
GOTO, A. ET AL.: "Genetic analysis of typical wet-type age-related macular de generation and polypoidal choroidal vasculopathy in Japanese population", JOURNAL OF OCULAR BIOLOGY, DISEASES, AND INFORMATICS., vol. 2, no. 4, 22 December 2009 (2009-12-22), pages 164 - 175, XP008152026 *
NG, T. K. ET AL.: "Multiple gene polymorphisms in the complement factor h gene are associated with exudative age-related macular degeneration in chinese", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE., vol. 49, no. 8, 1 April 2008 (2008-04-01), pages 3312 - 3317, XP002580199 *
RAYCHAUDHURI, S. ET AL.: "Associations of CFHR1-CFHR3 deletion and a CFH SNP to age-related macular degenerationi are not independent", NATURE GENETICS., vol. 42, no. 7, July 2010 (2010-07-01), pages 553 - 555, XP008152019 *
SPENCER, K. L. ET AL.: "Deletion of CFHR3 and CFHR1 genes in age-related macu lar degeneration", HUMAN MOLECULAR GENETICS., vol. 17, no. 7, 15 December 2007 (2007-12-15), pages 971 - 977, XP008151867 *

Also Published As

Publication number Publication date
EP2451983A4 (fr) 2012-12-05
CA2781595A1 (fr) 2011-01-13
WO2011006161A2 (fr) 2011-01-13
US20110014716A1 (en) 2011-01-20
EP2451983A2 (fr) 2012-05-16
EP2451983B1 (fr) 2015-05-06
US20120135884A1 (en) 2012-05-31
EP2963128A1 (fr) 2016-01-06
CA2781595C (fr) 2016-07-05
US8119348B2 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
WO2011006161A3 (fr) Compositions et procédés permettant de diagnostiquer et de traiter la dégénérescence maculaire
IL212066A (en) 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment
EP2371793A4 (fr) Procédés de préparation de 1,1-dichloro-2,3,3,3-tétrafluoropropène et de 2,3,3,3-tétrafluoropropène
IL222252A (en) A system, device and method for detecting and diagnosing biological arrhythmias
WO2013014286A3 (fr) Moyens et procédés de diagnostic et de surveillance de l'insuffisance cardiaque chez un sujet.
WO2008088858A3 (fr) Compositions et procédés comprenant des microarn pour traiter une néoplasie
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
WO2011095623A3 (fr) Miarn dans le diagnostic du cancer ovarien
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
EP2717758A4 (fr) Bande à capacité de données pour des diagnostic, surveillance et traitement médicaux
EP2586762A4 (fr) Procédé de fabrication de 1,1-dichloro-2,3,3,3-tétra-fluoropropène et de 2,3,3,3-tétrafluoropropène
IL218216A0 (en) Novel arylated camphenes, processes for their preparation and uses thereof
EP2260107A4 (fr) Analyses permettant de diagnostiquer et d évaluer des options de traitement pour la maladie de pompe
EP2490721A4 (fr) Compositions, procédés de traitement et de diagnostic de troubles liés à l'auto-immunité et procédé de fabrication de telles compositions
AU2009231892A8 (en) Methods of diagnosing, preventing and treating bone mass diseases
EP2500022A4 (fr) Agent antibactérien contre des bactéries pharmacorésistantes, procédé de criblage et usage associés
SI2448503T1 (sl) Skalpel, še zlasti za oftalmološko uporabo
WO2012078618A3 (fr) Prédiction et traitement de complications diabétiques
WO2009029587A3 (fr) Compositions et procédés pour le diagnostic et le traitement d'une dégénérescence maculaire
EP2917731A4 (fr) Protocoles diagnostiques, pronostiques, thérapeutiques et de criblage
EP2350318A4 (fr) Procédés, compositions et kits pour diagnostiquer, surveiller et traiter une maladie
EP2563043A4 (fr) Sonde ultrasonore, procédé de production à cet effet, et équipement de diagnostic ultrasonore
WO2012073111A3 (fr) Méthodes et compositions de contrôle de l'activité phagocytaire
ZA201105092B (en) Intravascular device, method for manufacturing same, and kits including same
WO2011156820A9 (fr) Compositions, méthodes et utilisations pour le traitement du diabète insulino-dépendant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797971

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2781595

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010797971

Country of ref document: EP